Meningitis Pipeline Summary

DelveInsight’s, “Meningitis - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meningitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Meningitis: Understanding

Meningitis: Overview

Meningitis refers to inflammation and irritation of the meninges surrounding the brain and spinal cord and may result from infectious or non-infectious causes, including bacteria, viruses, systemic inflammatory conditions, medications, and vaccinations. Bacterial meningitis is the most severe form and can be life-threatening; although historically fatal before the advent of antibiotics, it continues to have mortality rates of 25% or higher in some settings, particularly low-income countries. Despite advances in diagnosis, treatment, and vaccination, approximately 2.5 million cases of bacterial meningitis and 300,000 associated deaths were reported globally in 2024. Prevention remains challenging due to declining vaccine uptake, gaps in herd immunity, and disruptions to healthcare and vaccination services caused by natural and man-made disasters. Viral and aseptic meningitis are considerably more common than bacterial meningitis and are generally less severe, although they can still result in substantial morbidity.

Meningitis is inflammation of the meninges surrounding the brain and spinal cord and may result from bacterial, viral, fungal, or, less commonly, parasitic infections. Common bacterial causes include Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, Streptococcus agalactiae, and Listeria monocytogenes, while nonpolio enteroviruses are the predominant viral pathogens. Fungal meningitis mainly affects immunocompromised individuals and is commonly associated with Cryptococcus, Coccidioides, Aspergillus, and Candida. Rare parasitic causes include Angiostrongylus, Baylisascaris, and Naegleria fowleri.

The risk of atypical or opportunistic infections increases with immunosuppression, neurosurgery, trauma, cerebrospinal fluid shunts, and defects in protective barriers. When inflammation involves both the meninges and brain parenchyma, it is termed meningoencephalitis, which is more commonly viral in origin.

Meningitis typically develops when pathogens reach the central nervous system through hematogenous dissemination, neuronal transport, or direct/contiguous spread from nearby infected sites. In bacterial meningitis, organisms commonly colonize the nasopharynx, invade the bloodstream, and cross into the CNS, where they multiply in the subarachnoid space and trigger a strong inflammatory response. Viral meningitis often follows a similar process, with secondary viremia facilitating CNS invasion. The resulting release of inflammatory mediators, including IL-1, IL-6, and TNF, disrupts the blood-brain barrier and promotes cerebral edema, vascular dysfunction, ischemia, and neuronal injury. Pathogens may also access the CNS through neuronal pathways, although this mechanism is better established experimentally. Direct CNS infection can occur following trauma, neurosurgery, or placement of devices such as ventriculoperitoneal shunts, while contiguous spread may result from infections such as otitis media, mastoiditis, or sinusitis. Rare congenital defects involving the skull or spinal meninges can also provide a route for pathogens to enter the CNS.

Meningitis is primarily evaluated through a detailed clinical history, physical examination, and cerebrospinal fluid (CSF) analysis, obtained by lumbar puncture with measurement of opening pressure when feasible. Standard CSF testing includes Gram staining, cell count, glucose, protein, and culture, supplemented by PCR and other rapid molecular diagnostics when available. Additional pathogen-specific testing may be performed based on suspected etiology, including PCR for viral infections; cryptococcal antigen, fungal biomarkers, and cultures for fungal meningitis; acid-fast staining, culture, and molecular assays for tuberculosis; and CSF VDRL or Borrelia burgdorferi antibody testing for syphilis or Lyme disease, respectively. CSF should ideally be collected before antimicrobial therapy; however, in patients with suspected bacterial meningitis who are critically ill, treatment should not be delayed for lumbar puncture. Head CT before lumbar puncture is recommended for patients with risk factors for intracranial complications, such as significant altered mental status, recent seizures, focal neurological deficits, papilledema, severe immunocompromise, or relevant CNS disease, while routine CT in low-risk patients may unnecessarily delay treatment. Importantly, a normal CT does not exclude raised intracranial pressure or impending herniation. Blood cultures, serum glucose, electrolytes, and renal and hepatic function tests should also be performed to support diagnosis and management.

"Meningitis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Meningitis pipeline landscape is provided which includes the disease overview and Meningitis treatment guidelines. The assessment part of the report embraces, in depth Meningitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Meningitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Meningitis R&D. The therapies under development are focused on novel approaches to treat/improve Meningitis.

Meningitis Emerging Drugs Chapters

This segment of the Meningitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Meningitis Emerging Drugs

SP0230: Sanofi

SP0230 is a Sanofi investigational 5-valent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and B (ACWY+B), being developed for the prevention of invasive meningococcal disease, including meningitis. The program incorporates Sanofi’s MenB vaccine candidate and is designed to broaden protection against major Neisseria meningitidis serogroups in a single vaccine. SP0230 is currently in Phase II development for the treatment of meningitis.

IVIV 378: InventVacc Biologicals

IVIV 378 is a Haemophilus influenzae type a (Hia) glycoconjugate vaccine candidate being developed by InventVacc Biologicals to prevent invasive Hia infections, including meningitis. The vaccine is designed to induce protective immune responses against the Hia capsular polysaccharide and is administered intramuscularly (IM). InventVacc is advancing the candidate toward clinical development and manufacturing, supported by preclinical immunogenicity data. According to company’s pipeline the drug is in phase I stage of it’s development for the treatment of Haemophilus Influenzae Meningitis.

Further product details are provided in the report……..

Meningitis: Therapeutic Assessment

This segment of the report provides insights about the different Meningitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Meningitis
• There are approx. 10+ key companies which are developing the therapies for Meningitis. The companies which have their Meningitis drug candidates in the most advanced stage, i.e. Phase II include, Sanofi.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Meningitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Meningitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Meningitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meningitis drugs.

Meningitis Report Insights

• Meningitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Meningitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Meningitis drugs?
• How many Meningitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meningitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Meningitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Meningitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• InventVacc Biologicals
• Sanofi
• Bioversys
• LG Chem

Key Products

• IVIV 378
• SP0230
• BV100
• MDR-TB
• LR20062